2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Melanoma
137
Carcinoma, Renal Cell
52
Kidney Neoplasms
43
Leukemia, Myeloid, Acute
38
Neoplasm Metastasis
37
Leukemia
33
Lymphoma
30
Breast Neoplasms
26
Ovarian Neoplasms
24
Lymphoma, Non-Hodgkin
22
Carcinoma, Non-Small-Cell Lung
22
Skin Neoplasms
21
Precursor Cell Lymphoblastic Leukemia-Lymphoma
19
Neuroblastoma
18
Lymphoma, Follicular
18
Pancreatic Neoplasms
16
Lymphoma, Mantle-Cell
16
Leukemia, Lymphocytic, Chronic, B-Cell
16
Stomach Neoplasms
14
Neoplasms
14
Myelodysplastic Syndromes
14
Colorectal Neoplasms
13
Multiple Myeloma
12
Lymphoma, Large B-Cell, Diffuse
12
Lymphoma, B-Cell, Marginal Zone
12
Hodgkin Disease
12
Congenital Abnormalities
12
Uterine Cervical Neoplasms
11
Lymphoma, Large-Cell, Immunoblastic
11
Lung Neoplasms
11
Interventions
fludarabine
1
aldesleukin
1
Interleukin-2
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Cancer Metastatic
×
aldesleukin
×
Clear all
NCT04389229
2020-12-16
OVSTAR
Immetacyte Ltd
Phase 1/2
Withdrawn